Search PubMed⌕ Search

Biomedical subjects

T B Vree

Publications and source records attributed to T B Vree.

At least 181 records · Page 10Linked to original sources
PubMed1987

Deterioration of kidney function by high doses of co-trimoxazole in man.

High doses of co-trimoxazole in a patient with Pneumocystis carinii and impaired kidney function (creatinine clearance 10 ml/min) resulted in a declining renal clearance of the drug but did not affect the average creatinine clearance. The renal clearance of sulfamethoxazole and its metabolites 5-hydroxy-, N4-acetyl-, N4-acetyl-5-hydroxysulfamethoxazole decreased 80%, while the renal clearance of trimethoprim decreased 60%. The renal clearance of all compounds was evidently dependent on urine flow. The observed phenomena may be explained by the assumption that crystalluria occurred, obstructing kidney tubules. The crystalluria effect can be reversed by cessation of the drug or by lowering its dosage.

Adult↗
PubMed1987

Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on murine tumors in vivo has been disappointing. The purpose of our study was to investigate the pharmacokinetics of this drug as well as the possible mechanisms that produce sparsomycin toxicity. Tests on beagle dogs revealed that about 60% of the drug is eliminated by metabolic clearance, while 40% is eliminated by the kidneys. After a single bolus injection of 0.1 mg/kg sparsomycin without narcosis, sparsomycin was eliminated with a t beta 1/2 of 0.6-0.7 h, the AUC being 0.32-0.38 mg.h.l-1, and the volume of distribution (Vd) 0.26 l/kg. In addition to being subject to glomerular filtration, sparsomycin is probably also actively excreted and actively reabsorbed by the renal tubuli. Sparsomycin itself may inhibit its active tubular excretion, thus resulting in a decrease in the drug's renal clearance and its accumulation in the plasma. Sparsomycin appeared to be toxic primarily in the liver, disturbing its function and the synthesis of plasma proteins. Two out of five dogs developed hemorrhagic diathesis due to hypofibrinogenemia and deficiency of other blood-coagulation factors. Sparsomycin was not toxic to the bone marrow.

Animals↗
PubMed1987

Residues of sulphadimidine and its metabolites in eggs following oral sulphadimidine medication of hens.

The depletion of sulphadimidine (SDM) and its N4-acetyl and hydroxy metabolites was studied in eggs laid by hens after administration of either a single or multiple oral dosages of 100 mg SDM/kg. During medication and until 1 day after the last dose, the SDM and its metabolite concentrations in the egg white exceeded those in the egg yolk and reflected the plasma levels. In the period starting 2 days after the (last) dosage, the SDM concentration in the yolk became higher than in the egg white, and the drug depletion curves ran parallel. The mean maximum amount of SDM found in the whole egg was 1500 micrograms after a single and 1280 micrograms after multiple dosage. In eggs, traces of the N4-acetyl and 6-methylhydroxy metabolites could be detected (mainly in the egg white), and their concentrations were approximately 40 times lower than those of the parent drug. A highly significant correlation (P less than 0.005) was found between the development stage of the oocyte at the time of (last) medication and the amount of SDM found in the egg that developed from it. A period of 7 or 8 days after the (last) dosage of 100 mg SDM/kg/day is required to obtain SDM levels below 0.1 micrograms/g egg.

Animals↗
PubMed1987

Acetylation and hydroxylation of sulphatroxazole in the snail Cepaea hortensis and the slug Arion rufus.

The snail Cepaea hortensis can acetylate and hydroxylate sulphatroxazole via a pathway similar to that in man. The principal metabolic pathways, in order of decreasing rate, are hydroxylation, glucuronidation and acetylation. The slug Arion rufus also can acetylate and hydroxylate sulphatroxazole, although, in contrast to the snail, is rate of acetylation is higher than that of hydroxylation.

Acetylation↗
PubMed1987

Pharmacokinetics of sulphanilamide and its three acetyl metabolites in dairy cows and calves.

An intravenous low dosage of sulphanilamide (SAA) (14.0 mg/kg) to 6 pre-ruminant calves revealed a biphasic SAA plasma disposition with a mean elimination half-life of 4.1 h. The main metabolite in plasma was N4-acetylsulphanilamide (N4), which 4 hours after injection exceeded the parent SAA plasma concentration. Urinary recovery of SAA was 10 to 16% of the dose; of N4, it was at least 69%. Traces of the N1-acetyl (N1) metabolite and the doubly acetylated derivative (N1N4) were present in urine. The renal clearances of the N1 and N4 metabolites showed a tubular secretion pattern, which was at least 2 to 6 times higher than that of SAA. A single high oral SAA dose of 200 mg/kg to 3 dairy cows resulted in extensive metabolism of SAA into N4, N1, and N1N4 metabolites; their mean maximum plasma concentrations were 64, 48, 0.72 and 24 micrograms/ml, respectively. The mean disposition half-life of SAA in plasma and milk was 10 h. In milk the metabolite concentrations exceeded those in plasma; the N4 and N1N4 metabolite concentrations in milk exceeded that of SAA. The mean maximum concentrations of SAA, N4, N1, and N1N4 in milk were 52, 89, 2.3, and 98 micrograms/ml, respectively. For SAA and its metabolites, the binding to plasma and milk proteins was determined. No glucuronide or sulphate conjugates of SAA and its acetyl metabolites could be found in plasma, milk, or urine. Based on the sensitivity of the bioassay (0.2 micrograms SAA/ml), a withholding time of 5 days was suggested for milk following single oral SAA dosage of 200 mg/kg.

Animals↗
PubMed1987

Some pharmacokinetic data about furaltadone and nitrofurazone administered orally to preruminant calves.

A single oral dosage of furaltadone and nitrofurazone (14.0 mg/kg) to 5 preruminant calves (in a cross-over trial) revealed mean maximum plasma concentration of 2.5 and 3.5 microgram/ml, respectively, at approximately 3 h after administration. The final elimination half-lives of furaltadone and nitrofurazone were 2.5 and 5 h, respectively. Urinary recovery of these two nitrofurans in 3 calves revealed approximately 2% of the orally administered dose. The renal clearance of the unbound drugs did not differ (for both drugs approximately 0.42 ml/min/kg); furaltadone clearance was strongly related to urine flow.

Administration, Oral↗
PubMed1987

Acetylation, deacetylation and hydroxylation of sulphamethoxazole and N4-acetylsulphamethoxazole in the turtle Pseudemys scripta elegans.

The turtle Pseudemys scripta elegans is able to hydroxylate and acetylate Sulphamethoxazole in a way that is comparable to man, i.e. the rate and yield of hydroxylation equals that of the acetylation. The hydroxy metabolites 5-hydroxy- and N4-acetyl-5-hydroxysulphamethoxazole are not glucuronidated. N4-acetylsulphamethoxazole is neither deacetylated nor hydroxylated.

Acetylation↗
PubMed1987

Propylene glycol pharmacokinetics and effects after intravenous infusion in humans.

Knowledge of the pharmacokinetics of propylene glycol (PG) is scarce, though it is used in a number of preparations for intravenous use. Although systemic toxicity appears to be uncommon, PG has been reported to cause lactic acidosis and other adverse effects. We describe a rapid gas chromatographic assay method for PG and the plasma pharmacokinetics after intravenous administration to six patients on nine occasions. The pharmacokinetics were nonlinear, based on a saturable clearance. The apparent first-order half-life was 2.3 +/- 0.7 h. There was no evidence of lactic acidosis, hemolysis, or increase in osmolality at 3-15 g/m2 PG infused over periods of 4 h.

Adult↗
PubMed1987

Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients--preliminary results.

Seven intensive care patients were sedated with prolonged infusion of midazolam. One patient received a continuous infusion of midazolam for the treatment of status epilepticus. A bolus injection of 5 mg was administered, followed by infusion of 4-14 mg/hour depending on the required level of sedation. The length of infusion varied between 80 and 360 hours. The plasma concentrations of the midazolam during infusion were between 500-1000 ng/ml. All the patients were adequately sedated. The plasma elimination half-life of midazolam and its main metabolite, 1-OH-midazolam glucuronide, after stopping the infusion varied from 4-12 hours.

Adolescent↗
PubMed1987

Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.

Some of the new quinolone derivatives may be of value in the treatment of respiratory tract infections. It has been demonstrated that enoxacin, pefloxacin and ciprofloxacin, but not ofloxacin, decreased the metabolic clearance of the bronchodilator theophylline. This resulted in elevated plasma theophylline concentrations and, in some of the patients, theophylline toxicity. When the pharmacokinetic parameters of enoxacin, pefloxacin, ciprofloxacin and ofloxacin obtained in the present study were compared with those obtained from other studies in healthy volunteers not given concomitant theophylline, there was no evidence of theophylline influencing the clearance of the investigated quinolones.

Aged↗
PubMed1987

Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses.

Plasma disposition, protein binding, urinary recovery, and renal clearance of sulfamethazine (SMZ), sulfamerazine (SMR), and sulfadiazine (SDZ) and their N4-acetyl and hydroxy derivatives were studied in 4 horses in a crossover trial. The plasma concentration-time curves of the metabolites paralleled those of the parent drug in the elimination phase. Sulfamethazine and SMR were extensively metabolized. In plasma and urine, the main metabolite of the 3 sulfonamides tested was the 5-hydroxypyrimidine derivative, which was highly glucuronidated. Difference in elimination half-life of SMZ, SMR, and SDZ could be related to difference in metabolism and renal clearance values. Metabolism speeds drug elimination, producing compounds with higher renal clearance values than those of the parent drug. Methyl substitution in the pyrimidine side chain increased hydroxylation of the parent drug, but prolonged the persistence of the sulfonamides studied in the body. The high concentration of N4-acetyl and hydroxy metabolites of SMZ and SMR in plasma and urine decreased the potential antibacterial activity of the parent drugs. Sulfadiazine was less metabolized, and microbiologically determined SDZ concentrations in plasma and urine were slightly lower than those measured by high-performance liquid chromatography.

Animals↗